Vertex Pharma Acquires ViroChem For $395M
In a strategic move meant to strengthen its hepatitis C treatment pipeline, Vertex Pharmaceuticals Inc. has acquired Canada-based ViroChem Pharmaceuticals Inc. for around $395 million, including $100 million in cash....To view the full article, register now.
Already a subscriber? Click here to view full article